TESARO, Inc. (NASDAQ:TSRO) Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TESARO, Inc. (NASDAQ TSRO) traded up 2.43% on Wednesday, reaching $121.62. The company had a trading volume of 977,112 shares. The firm’s market capitalization is $6.59 billion. The stock’s 50-day moving average price is $121.03 and its 200 day moving average price is $138.94. TESARO, Inc. has a 52-week low of $96.52 and a 52-week high of $192.94.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm’s revenue was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.28) earnings per share. On average, equities analysts anticipate that TESARO, Inc. will post ($8.61) earnings per share for the current fiscal year.

WARNING: “James O. Armitage Sells 10,000 Shares of TESARO, Inc. (TSRO) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/20/james-o-armitage-sells-10000-shares-of-tesaro-inc-tsro-stock.html.

TSRO has been the subject of a number of research reports. Gabelli initiated coverage on TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective for the company. ValuEngine raised TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Oppenheimer Holdings, Inc. initiated coverage on TESARO in a research note on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective for the company. Wedbush raised TESARO to an “outperform” rating and set a $168.00 price objective for the company in a research note on Monday, June 5th. Finally, Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a “buy” rating in a research note on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $171.42.

Several institutional investors have recently made changes to their positions in the company. Achmea Investment Management B.V. acquired a new stake in shares of TESARO during the second quarter valued at about $234,000. Public Employees Retirement System of Ohio grew its stake in shares of TESARO by 82.4% during the second quarter. Public Employees Retirement System of Ohio now owns 36,667 shares of the biopharmaceutical company’s stock valued at $5,128,000 after acquiring an additional 16,569 shares in the last quarter. Intellectus Partners LLC grew its stake in shares of TESARO by 17.7% during the second quarter. Intellectus Partners LLC now owns 6,310 shares of the biopharmaceutical company’s stock valued at $883,000 after acquiring an additional 950 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of TESARO by 20.8% during the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after acquiring an additional 11,706 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in shares of TESARO by 291.7% during the second quarter. Cubist Systematic Strategies LLC now owns 7,105 shares of the biopharmaceutical company’s stock valued at $994,000 after acquiring an additional 5,291 shares in the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.